LL-37 Research: The Human Cathelicidin Peptide and What Laboratory Studies Have Examined

A research-focused look at LL-37, the only human cathelicidin: how it is processed from hCAP-18, its amphipathic helix, membrane studies, vitamin D regulation and immune signalling findings.

Share

LL-37 is a 37-residue peptide that has become one of the most studied host defence peptides in the literature. It is the only member of the cathelicidin family encoded in the human genome, and it sits at an interesting crossroads: it was first described as an antimicrobial molecule, but a large body of later work has examined it as a signalling molecule within the innate immune system. This article summarises what published laboratory research has reported about LL-37's origin, structure and biology, for researchers deciding whether it belongs in their own work.

Discovery: from FALL-39 to LL-37

The story begins in 1995, when Agerberth and colleagues, working in Hans Boman's group in Stockholm, used a gene-based search for human relatives of antibacterial peptides already known from other mammals. They identified a cDNA encoding a predicted 39-residue peptide they named FALL-39, after its first four amino acids, and reported that it was cysteine-free and expressed in bone marrow and testis (PNAS, 1995).

A year later, Gudmundsson and colleagues described the human gene in more detail and showed that the mature peptide actually released in granulocytes is two residues shorter. Because it begins with two leucines and is 37 residues long, it was renamed LL-37 (European Journal of Biochemistry, 1996). The sequence is LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES.

The cathelicidin precursor and how LL-37 is released

Cathelicidins share a common architecture: a conserved N-terminal "cathelin-like" domain followed by a variable C-terminal antimicrobial domain. Zanetti's review in the Journal of Leukocyte Biology describes how this family varies widely across mammals, from the single human gene to many in cattle and pigs.

In humans the full precursor is called hCAP-18 (human cationic antimicrobial protein of 18 kDa). It is stored in the specific granules of neutrophils in its inactive form. Sørensen and colleagues showed in Blood (2001) that LL-37 is cut from hCAP-18 outside the cell after release, and that the enzyme responsible is proteinase 3, a serine protease from a different granule type. This separation of precursor and processing enzyme is one reason LL-37 research often distinguishes carefully between the precursor protein and the mature peptide.

Structure: an amphipathic helix that depends on its environment

LL-37 is strongly cationic, carrying a net positive charge of about +6 at neutral pH, and it can fold into an amphipathic alpha-helix with hydrophobic and charged residues on opposite faces. Crucially, that helix is not fixed. Johansson and colleagues reported in the Journal of Biological Chemistry (1998) that LL-37's helical content, measured by circular dichroism, changes with salt concentration, pH and peptide concentration, and that its antibacterial activity in their assays tracked those conformational changes.

Two further structural studies are frequently cited:

  • Membrane studies. Oren and colleagues (Biochemical Journal, 1999) examined LL-37 in phospholipid membranes and reported that it lies largely parallel to the membrane surface and can oligomerise, findings they related to its relatively low selectivity between bacterial and mammalian cells in their experiments.
  • High-resolution NMR. Wang (Journal of Biological Chemistry, 2008) solved the structure of LL-37 in detergent micelles, describing a curved, largely helical structure with a bend in its N-terminal half, and identified KR-12, a 12-residue fragment that retained antibacterial activity in vitro. KR-12 and other fragments have since been used widely in structure-activity work.

Because LL-37's conformation is so sensitive to buffer, salt and concentration, method details matter when comparing studies. Our article on circular dichroism explains how helical content is measured and why solvent choice changes the result.

Regulation by vitamin D

One of the more widely cited findings about LL-37 concerns how its gene, CAMP, is switched on. Wang and colleagues reported in the Journal of Immunology (2004) that the active form of vitamin D, 1,25-dihydroxyvitamin D3, directly induces cathelicidin gene expression, and identified a vitamin D response element in the gene's promoter. In 2006, Liu and colleagues reported in Science that activating Toll-like receptors on cultured human monocytes and macrophages increased expression of the vitamin D receptor and the enzyme that activates vitamin D, leading to cathelicidin induction in those cells. These papers linked an innate immune sensor, a vitamin pathway and an antimicrobial peptide in one cell-culture model.

Beyond antimicrobial activity: signalling findings

Much of the past two decades of LL-37 research has focused on effects that have little to do with killing microbes directly:

  • Angiogenesis signalling. Koczulla and colleagues (Journal of Clinical Investigation, 2003) reported that LL-37 stimulated endothelial cell proliferation and vessel formation in their experimental models, and attributed the effect to the formyl peptide receptor-like 1 (FPRL1).
  • Nucleic acid sensing. Lande and colleagues (Nature, 2007) reported that LL-37 can bind self-DNA and form complexes that plasmacytoid dendritic cells then sense through Toll-like receptor 9, an observation they connected to inflammatory signalling in skin. This work is often cited as an example of a host defence peptide acting as an immune modulator rather than a simple antibiotic.

Taken together, this literature shows why LL-37 is described in reviews as multifunctional, and also why results depend so much on cell type, concentration and model.

Practical considerations for laboratory work

Researchers working with synthetic LL-37 typically pay attention to a few points:

  • Aggregation and adsorption. Cationic, amphipathic peptides can self-associate and stick to plastic and glass surfaces, which can reduce the effective concentration in an assay. Low-binding labware and consistent handling help with reproducibility.
  • Buffer and salt. Since structure and in vitro activity vary with ionic strength, reporting buffer composition precisely makes results easier to compare.
  • Identity and purity. A 37-residue sequence is long enough that deletion and truncation impurities are a real possibility in synthesis. Mass spectrometry, HPLC purity and, where needed, sequencing data on the certificate of analysis are worth checking.
  • Counter-ion. LL-37 is usually supplied as a TFA or acetate salt, and residual TFA can interfere with some cell-based assays.

Summary

LL-37 is the processed, active form of human cathelicidin hCAP-18, a cationic peptide whose helical structure depends heavily on its environment. Published laboratory research has examined its antimicrobial activity, its membrane interactions, its regulation by vitamin D and its role in immune signalling through receptors such as FPRL1 and TLR9. Its sensitivity to conditions makes careful method reporting and well-characterised material especially important.

References

  • Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proceedings of the National Academy of Sciences. 1995;92(1):195-199. doi:10.1073/pnas.92.1.195.
  • Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. European Journal of Biochemistry. 1996;238(2):325-332. doi:10.1111/j.1432-1033.1996.0325z.x.
  • Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. Journal of Leukocyte Biology. 2004;75(1):39-48. doi:10.1189/jlb.0403147.
  • Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951-3959. doi:10.1182/blood.v97.12.3951.
  • Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. Journal of Biological Chemistry. 1998;273(6):3718-3724. doi:10.1074/jbc.273.6.3718.
  • Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochemical Journal. 1999;341(3):501-513. doi:10.1042/bj3410501.
  • Wang G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. Journal of Biological Chemistry. 2008;283(47):32637-32643. doi:10.1074/jbc.m805533200.
  • Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. Journal of Immunology. 2004;173(5):2909-2912. doi:10.4049/jimmunol.173.5.2909.
  • Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-1773. doi:10.1126/science.1123933.
  • Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. Journal of Clinical Investigation. 2003;111(11):1665-1672. doi:10.1172/jci17545.
  • Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564-569. doi:10.1038/nature06116.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.